Daliresp and Otitis - a phase IV clinical study of FDA data

Summary:

Otitis is found among people who take Daliresp, especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Daliresp and have Otitis. It is created by eHealthMe based on reports of 4,030 people who have side effects when taking Daliresp from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 06, 2023

4,030 people reported to have side effects when taking Daliresp.
Among them, 25 people (0.62%) have Otitis.

What is Daliresp?

Daliresp has active ingredients of roflumilast. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 4,076 Daliresp users for its effectiveness, alternative drugs and more.

What is Otitis?

Otitis (ear infection) is found to be associated with 2,450 drugs and 1,667 conditions by eHealthMe.

Number of Daliresp and Otitis reports submitted per year:

Time on Daliresp when people have Otitis *:

Gender of people who have Otitis when taking Daliresp *:

female: 54.17 %
male: 45.83 %

Age of people who have Otitis when taking Daliresp *:

Common drugs people take besides Daliresp *:

Common side effects people have besides Otitis *:

Sinusitis (inflammation of sinus): 9 people, 36.00%
Cellulitis (infection under the skin): 8 people, 32.00%
Pneumonia: 5 people, 20.00%
Breathing Difficulty: 5 people, 20.00%
Oropharyngeal Pain: 4 people, 16.00%
Productive Cough: 4 people, 16.00%
Wheezing (a high-pitched whistling sound made while you breath): 3 people, 12.00%
Ruptured Eardrum (tear in eardrum): 3 people, 12.00%
Infection: 3 people, 12.00%
Infusion Related Reaction: 3 people, 12.00%

Common conditions people have *:

Immunodeficiency Common Variable: 12 people, 48.00%
Immunodeficiency: 4 people, 16.00%
High Blood Cholesterol: 2 people, 8.00%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 1 person, 4.00%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 1 person, 4.00%
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 1 person, 4.00%
Bronchitis Chronic (inflammation of the mucous membrane in the bronchial tubes- chronic): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Daliresp and have Otitis?

Check whether Otitis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Otitis and when was it recovered:

Otitis in Daliresp

Expand to all the drugs that have ingredients of roflumilast:

Otitis and drugs with ingredients of roflumilast (12 reports)

Alternative drugs to, pros and cons of Daliresp:

Daliresp (4,076 reports)

Common Daliresp side effects:

Browse all side effects of Daliresp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Otitis treatments and more:

Otitis (29,228 reports)

COVID vaccines that are related to Otitis:

Common drugs associated with Otitis:

All the drugs that are associated with Otitis:

Otitis (2,450 drugs)

Common conditions associated with Otitis:

All the conditions that are associated with Otitis:

Otitis (1,667 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on roflumilast (the active ingredients of Daliresp) and Daliresp (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.